Clinical trial
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing…
NCT00140049 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00140049 |
|---|---|
| Title | A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma |
| Official title | A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular… |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Glaucoma, Open Angle, Ocular Hypertension |
| Intervention type | Drug |
| Interventions | Xalacom, Cosopt |
| Enrollment | 238 |
| Start date | Jul 1, 2005 |
| Completion | Jul 1, 2006 |
| First posted | Aug 31, 2005 |
| Last update posted | Feb 18, 2021 |
| Countries | France, Germany, Greece, Italy, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: